News | Cardiovascular Business | August 17, 2022

Memorial Cardiac and Vascular Institute Adds Cardiologists to its Physician Roster

Memorial Healthcare System, a South Florida-based academic medical center, has added a diverse trio of doctors to its cardiac care team. 

Adetola Ladejobi, MD

Adetola Ladejobi, MD 


August 17, 2022 — Memorial Healthcare System, a South Florida-based academic medical center, has added a diverse trio of cardiologists to its cardiac care team. The fellowship-trained physicians have all worked internationally during their medical careers and join Memorial Cardiac and Vascular Institute as it grows its research and academic programs. 

Adetola Ladejobi, MD, an electrophysiologist, comes to Memorial from the Mayo Clinic, where he completed two fellowships and was an instructor at its college of medicine. Dr. Ladejobi is focused on patient care, research, quality improvement, and healthcare operations. A native of Nigeria, “Tola” earned a master’s degree in public health from Harvard University and has also worked as a strategic consultant to healthcare systems, insurance companies, and Fortune 100 companies. 

Lynda Otalvaro, MD, a clinical cardiologist, was most recently at the University of Florida where she was an assistant professor at UF’s College of Medicine and director of its Lipid Clinic. In the time prior to that, Dr. Otalvaro worked as an adult non-invasive cardiologist in Kentucky. She finished first in her class at Universidad Libre, School of Medicine in Cali, Colombia before coming to the University of Miami’s Miller School of Medicine. While at UM, Dr. Otalvaro completed an internal medicine residency and fellowship in cardiology. 

Sarah Rosanel, MD, completed both an internal medicine residency and cardiovascular disease fellowship at Maimonides Medical Center in Brooklyn, NY. A clinical cardiologist, Dr. Rosanel earned degrees from the Israel Institute of Technology’s Technion American Medical School and Yeshiva University in New York. 

“The capabilities, accomplishments, and diverse backgrounds of these physicians will
enhance Memorial’s offerings as an academic medical center, on par with larger, university-based systems,” said Dr. Michael Cortelli, chief of the Memorial Cardiac and Vascular Institute. “Their clinical, research, and academic expertise will benefit our patients and doctors alike.” 

Memorial’s Cardiac & Vascular Institute is a cardiovascular care leader, offering a wide array of services dedicated to the prevention, detection, and treatment of cardiovascular disease. Its multi-disciplinary specialists collaborate using sophisticated diagnostic equipment and facilities. Physician-review panels and nurses regularly review cardiovascular care outcomes to ensure quality assurance that utilizes computerized data collection. 

With extraordinary medical expertise, advanced technology and exacting quality guidelines, Memorial Cardiac & Vascular Institute offers a superior level of cardiovascular care. 

For more information: https://www.mhs.net/ 


Related Content

News | Heart Failure

October 3, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products ...

Home October 03, 2022
Home
News | Heart Failure

September 29, 2022 — Bloodstream levels of a protein fragment called endotrophin can be used to predict outcomes in ...

Home September 29, 2022
Home
News | Heart Failure

September 28, 2022 — A University of Massachusetts Amherst nurse engineer is leading a team of researchers who are ...

Home September 28, 2022
Home
News | Heart Failure

September 19, 2022 — A first-in-human (FIH) study using the ModulHeart device (Puzzle Medical Devices Inc.) has ...

Home September 19, 2022
Home
News | Heart Failure

September 15, 2022 — Today, aortic stenosis (AS) is one of the most common and serious valve disease problems [1]. It ...

Home September 15, 2022
Home
News | Heart Failure

September 14, 2022 — Minimally invasive, catheter-based transcatheter aortic valve replacement (TAVR) has revolutionized ...

Home September 14, 2022
Home
News | Heart Failure

September 2, 2022 — Dapagliflozin reduces the risk of cardiovascular death or worsening heart failure in heart failure ...

Home September 02, 2022
Home
News | Heart Failure

September 2, 2022 — Acetazolamide added to intravenous loop diuretics decreases congestion within three days in patients ...

Home September 02, 2022
Home
News | Heart Failure

September 2, 2022 — Percutaneous coronary intervention (PCI) does not reduce all-cause mortality or heart failure ...

Home September 02, 2022
Home
News | Heart Failure

August 29, 2022 — Detailed results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) ...

Home August 29, 2022
Home
Subscribe Now